TRDA insider transactions
Entrada Therapeutics Inc. (TRDA) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
Recent Form 3, 4, and 5 filings for TRDA
- SEC Form 4 filed by Director Parmar Kush4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- SEC Form 4 filed by Director Kim Peter S4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- SEC Form 4 filed by Director Chapman Gina4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- SEC Form 4 filed by Director Radhakrishnan Maha4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- SEC Form 4 filed by Director Thistle Mary4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- SEC Form 4 filed by Director Zeiher Bernhardt G4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Director Zeiher Bernhardt G bought $29,316 worth of shares (5,000 units at $5.86) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- President, Research & Develop. Sethuraman Natarajan sold $398,810 worth of shares (25,907 units at $15.39) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 216,317 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- President & COO Dowden Nathan J exercised 15,000 shares at a strike of $1.74 and sold $229,953 worth of shares (15,000 units at $15.33) as part of a pre-agreed trading plan (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- SEC Form 4 filed by Wentworth Kory James4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- SEC Form 4 filed by Entrada Therapeutics Inc.4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- SEC Form 4 filed by Entrada Therapeutics Inc.4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Chief Financial Officer Wentworth Kory James sold $97,892 worth of shares (7,988 units at $12.25), decreasing direct ownership by 5% to 137,987 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- CEO Doshi Dipal was granted 139,400 shares and covered exercise/tax liability with 29,050 shares, increasing direct ownership by 27% to 526,014 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Chief Financial Officer Wentworth Kory James was granted 44,600 shares and covered exercise/tax liability with 8,651 shares, increasing direct ownership by 33% to 145,975 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- President & COO Dowden Nathan J was granted 55,800 shares and covered exercise/tax liability with 21,261 shares, increasing direct ownership by 19% to 213,598 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- President, Research & Develop. Sethuraman Natarajan covered exercise/tax liability with 11,475 shares and was granted 55,800 shares, increasing direct ownership by 22% to 242,224 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Chief Financial Officer Wentworth Kory James sold $88,932 worth of shares (8,910 units at $9.98), decreasing direct ownership by 7% to 110,026 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Large owner Baker Bros. Advisors Lp bought $261,846 worth of shares (28,867 units at $9.07) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Director Parmar Kush sold $1,760,000 worth of shares (200,000 units at $8.80) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Large owner 5am Ventures V, L.P. sold $1,760,000 worth of shares (200,000 units at $8.80) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Large owner Baker Bros. Advisors Lp bought $1,352,587 worth of shares (178,044 units at $7.60) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- CEO Doshi Dipal covered exercise/tax liability with 8,723 shares, decreasing direct ownership by 2% to 415,664 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- President & COO Dowden Nathan J covered exercise/tax liability with 1,746 shares, decreasing direct ownership by 0.97% to 179,059 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- President, Research & Develop. Sethuraman Natarajan covered exercise/tax liability with 1,760 shares, decreasing direct ownership by 0.88% to 197,899 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Chief Financial Officer Wentworth Kory James covered exercise/tax liability with 1,734 shares, decreasing direct ownership by 1% to 118,936 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Director Parmar Kush sold $202,554 worth of shares (27,000 units at $7.50) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Large owner 5am Ventures V, L.P. sold $202,554 worth of shares (27,000 units at $7.50) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Director Parmar Kush sold $866,632 worth of shares (125,000 units at $6.93) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Large owner 5am Ventures V, L.P. sold $866,632 worth of shares (125,000 units at $6.93) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Amendment: Director Kim Peter S bought $731,682 worth of shares (50,000 units at $14.63), increasing direct ownership by 74% to 117,412 units (SEC Form 4)4/A - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- SEC Form 4 filed by Director Parmar Kush4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- SEC Form 4 filed by Director Kim Peter S4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- SEC Form 4 filed by Director Thistle Mary4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- SEC Form 4 filed by Director Zeiher Bernhardt G4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- SEC Form 4 filed by Director Chapman Gina4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- SEC Form 4 filed by Director Radhakrishnan Maha4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- SEC Form 3 filed by new insider Radhakrishnan Maha3 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Chief Financial Officer Wentworth Kory James exercised 11,134 shares at a strike of $2.10, increasing direct ownership by 10% to 120,670 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Chief Financial Officer Wentworth Kory James sold $19,035 worth of shares (1,784 units at $10.67), decreasing direct ownership by 2% to 109,536 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- CEO Doshi Dipal was granted 116,200 shares and covered exercise/tax liability with 17,566 shares, increasing direct ownership by 30% to 424,387 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Chief Financial Officer Wentworth Kory James was granted 42,400 shares and covered exercise/tax liability with 4,929 shares, increasing direct ownership by 51% to 111,320 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- President & COO Dowden Nathan J was granted 60,800 shares and covered exercise/tax liability with 5,144 shares, increasing direct ownership by 44% to 180,805 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- President, Research & Develop. Sethuraman Natarajan was granted 60,800 shares and covered exercise/tax liability with 6,138 shares, increasing direct ownership by 38% to 199,659 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Large owner Mpm Bioventures 2018, L.P. sold $917,111 worth of shares (44,722 units at $20.51) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Large owner Mpm Bioventures 2014, L.P. sold $917,111 worth of shares (44,722 units at $20.51) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Chief Financial Officer Wentworth Kory James exercised 6,000 shares at a strike of $2.10 and sold $119,948 worth of shares (6,000 units at $19.99) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- President, Research & Develop. Sethuraman Natarajan sold $320,620 worth of shares (15,891 units at $20.18), decreasing direct ownership by 10% to 144,997 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- President, Research & Develop. Sethuraman Natarajan sold $82,300 worth of shares (4,109 units at $20.03), decreasing direct ownership by 2% to 160,888 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Chief Financial Officer Wentworth Kory James exercised 6,000 shares at a strike of $2.10 and sold $172,562 worth of shares (8,637 units at $19.98), decreasing direct ownership by 3% to 73,849 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- President, Research & Develop. Sethuraman Natarajan sold $339,281 worth of shares (18,219 units at $18.62), decreasing direct ownership by 10% to 164,997 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- President, Research & Develop. Sethuraman Natarajan sold $10,800 worth of shares (600 units at $18.00), decreasing direct ownership by 0.33% to 183,216 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- President & COO Dowden Nathan J sold $13,552 worth of shares (847 units at $16.00), decreasing direct ownership by 0.67% to 125,149 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Chief Financial Officer Wentworth Kory James sold $47,832 worth of shares (3,195 units at $14.97), decreasing direct ownership by 4% to 76,486 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- President & COO Dowden Nathan J sold $34,753 worth of shares (2,303 units at $15.09), decreasing direct ownership by 2% to 125,996 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Chief Scientific Officer Sethuraman Natarajan sold $49,004 worth of shares (3,242 units at $15.12), decreasing direct ownership by 2% to 183,816 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- CEO Doshi Dipal covered exercise/tax liability with 8,722 shares, decreasing direct ownership by 3% to 325,753 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Chief Financial Officer Wentworth Kory James covered exercise/tax liability with 1,731 shares, decreasing direct ownership by 2% to 79,681 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- President & COO Dowden Nathan J covered exercise/tax liability with 1,808 shares, decreasing direct ownership by 1% to 128,299 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Chief Scientific Officer Sethuraman Natarajan covered exercise/tax liability with 1,756 shares, decreasing direct ownership by 0.93% to 187,058 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)